CI-1044

Research use only, not for human use.

CI-1044 is a potent, selective and orally bioavailable PDE4 inhibitor with IC50 of 0.27 uM.

CI-1044 is a potent, selective and orally bioavailable PDE4 inhibitor with IC50 of 0.27 uM, displays high selectivity for PDE4 versus PDE1/3/5, and no PDE4 subtype (4A-D) selectivities; exhibits efficient in vitro inhibition of TNFα release from hPBMC and hWB with IC50 of 0.34 and 0.84 uM, respectively; exhibits potent in vivo activity in antigen-induced eosinophil recruitment in rats (ED50=3.2 mg/kg, p.o.).Asthma Phase 1 Clinical

CI1044

Angiogenesis

PDE

PDE

Inflammation/Immunology

Asthma

197894-84-1

397.44

C23H19N5O2

>98% (HPLC)

DMSO : 125 mg/mL 314.52 mM

Nc1cc2CCN3C(=O)[C@H](NC(=O)c4cccnc4)N=C(c5ccccc5)c(c1)c23

(R)-N-(9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)nicotinamide

(-20℃)

With Ice Pack

≥ 2 years